Health Trials

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

ConditionsProstate AdenocarcinomaStage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorJonsson Comprehensive Cancer Center

About this trial

This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.

Eligibility criteria

Qualifiers

Ability to understand a written informed consent document, and the willingness to sign it

Age >= 18 years

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

History/physical examination with digital rectal examination of the prostate within 8 weeks prior to registration

Disqualifiers

Patients with neuroendocrine or small cell carcinoma of the prostate

Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years

Regional lymph node involvement

Evidence of distant metastases

Trial design

Treatments tested in this trial

  • High-Dose Rate Brachytherapy
  • Stereotactic Body Radiation Therapy

Treatment groups

52 Participants
are divided into 1 treatment group

Sponsors and collaborators

Jonsson Comprehensive Cancer Center

Lead sponsor

Source ClinicalTrials.gov